Last updated: February 23, 2026
What is NDC 62135-0491?
NDC 62135-0491 refers to Ibrutinib (brand name Imbruvica), a targeted therapy approved for various hematologic malignancies. The drug is indicated for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström’s macroglobulinemia, and other B-cell malignancies. It is marketed by AbbVie and Johnson & Johnson (Janssen).
Market Size and Growth Drivers
Current Market Landscape
| Indicator |
Data |
| Global Hematologic Malignancies Market |
USD 22 billion (2022 estimate) |
| Ibrutinib's Market Penetration |
Approx. USD 4.5 billion in 2022 (estimated global sales) |
| Key Competitors |
Acalabrutinib (Calquence), Zanubrutinib (Brukinsa), BTK inhibitors in pipeline |
| Prescription Volume (US) |
Approx. 400,000 annually (estimated) |
Growth Drivers
- Increasing incidence of hematological cancers: Mantle cell lymphoma and CLL cases rising globally.
- Expanding indications: Approval for marginally new indications and combination therapies.
- Pipeline alternatives: Development of next-generation BTK inhibitors, but Ibrutinib retains dominant market share.
- Pricing policies: Reimbursement coverage and high pricing favor sustained revenue.
Market Risks
- Generic/ biosimilar threats: Patent expiry in select markets could introduce competition.
- Pricing pressure: Payers aim to reduce drug costs, potentially limiting reimbursement.
- Adverse events and safety concerns: May influence prescriber preference.
Regulatory Status and Pricing
US Market
| Year of FDA Approval |
2013 (initial approval for MCL, CLL) |
| Current Average Wholesale Price (AWP) |
USD 13,000 – 15,000 per month (vial pricing varies) |
| Monthly Treatment Cost |
Approx. USD 14,000 (average retail price) |
| Yearly Revenue Estimate (2022) |
USD 4.5 billion |
International Markets
- Pricing varies significantly by country, generally lower than US prices.
- Regulatory approvals span over 80 countries.
- Health authorities like NICE (UK) evaluate cost-effectiveness, influencing access.
Price Projections (2023–2028)
| Year |
Estimated Global Sales (USD billion) |
Assumptions |
| 2023 |
4.7 |
Continued growth in US, stable European markets |
| 2024 |
5.1 |
Expansion into newer indications, price adjustments |
| 2025 |
5.4 |
Patent protection remains, pipeline acceleration remains limited |
| 2026 |
4.9 |
Patent cliffs approaching, biosimilar entry anticipated in select regions |
| 2027 |
4.2 |
Increased biosimilar competition, price erosion |
| 2028 |
3.8 |
Further biosimilar penetration, some market exits |
Notes:
- The forecast assumes annual growth of 6-8% for the next two years, tapering off as biosimilars gain market traction.
- Patent expiry expected in key markets by 2027.
- Price erosion of up to 30% expected in mature markets post-patent cliff.
Competitive & Pipeline Outlook
- The pipeline includes acalabrutinib and zanubrutinib, which could challenge Ibrutinib's dominance.
- Biosimilar development is underway in China, Europe, and the US.
- Several combination regimens are under clinical trial, which could alter the treatment landscape.
Market Entry and Strategic Opportunities
- Emerging markets: Growing adoption driven by expanding healthcare infrastructure.
- Value-based pricing: Engagement with payers for outcomes-based reimbursement.
- New indications: Investigating additional hematology and oncology indications offers sales potential.
Key Takeaways
- Ibrutinib maintains leading market share in targeted B-cell malignancies.
- Revenue is projected to remain robust until patent expiration, with prices declining thereafter.
- Competition from biosimilars and next-generation inhibitors will primarily influence market dynamics post-2026.
- Price erosion and generics will steadily lower the drug’s revenue, necessitating strategic diversification for manufacturers.
Frequently Asked Questions
1. When will the patent for NDC 62135-0491 expire?
Patents are expected to expire in the US in 2027, with potential extensions and biosimilar entry in subsequent years.
2. What are the main competitors for Ibrutinib?
Acalabrutinib (Calquence) and zanubrutinib (Brukinsa) are the primary alternatives approved for similar indications.
3. How does biosimilar competition affect pricing?
Introduction of biosimilars typically leads to price reductions of 20-30% in developed markets.
4. Which regions have the highest sales growth potential?
Emerging markets like China, India, and Latin America have significant growth potential due to increasing healthcare access and unmet needs.
5. How are payer policies influencing pricing?
Payers seek cost-effective treatment options, pressuring manufacturers for discounts, especially as biosimilars enter the market.
References
- IQVIA. (2022). Global Oncology Market Reports.
- FDA. (2013). Approval Letters for Ibrutinib.
- NICE. (2021). Assessment Reports — Ibrutinib.
- GlobalData. (2022). Hematologic Cancer Drugs Market Forecast.
- Scrip Intelligence. (2022). Biosimilars and Competitive Dynamics in Hematology.
